FindDrugs.org

SkinnyRx Weight Loss / GLP-1 Review

Weight Loss / GLP-1 · Reviewed Sep 24, 2026

5.68/10
SkinnyRx operator trust5.59/10See the full SkinnyRx brand review
Clinician accessCash-pay

Our verdict

SkinnyRx, the consumer brand of Lean Rx, Inc. (Sacramento, CA), is a direct-to-consumer telehealth platform selling compounded semaglutide and tirzepatide in injectable, sublingual, and tablet forms with no scheduled appointment . Its consumer ratings are strong (Trustpilot 4.8 across 5,266 reviews) and access is fast. But it carries notable transparency and legal red flags: an intro-price-then-standard-price pattern, a compounding pharmacy it does not name on the pages we reviewed, a February 2026 FDA marketing warning letter, and a class action over its oral tirzepatide. That mix places it near the bottom of the ranked GLP-1 field.

Price

See site

Visit SkinnyRx

We may earn a commission if you sign up through this link. It never affects rankings or scores. Not medical advice.

Key takeaways

  • Direct-to-consumer telehealth (Lean Rx, Inc., Sacramento CA); compounded semaglutide and tirzepatide in injection, sublingual, and tablet forms, all 50 states
  • Fast async access with no scheduled appointment; strong Trustpilot rating (4.8 across 5,266 reviews, on a paid Trustpilot subscription)
  • SkinnyRx names no compounding pharmacy on the pages we reviewed — confirmed absent on those rendered pages, which refer only to "our partner pharmacies", "503A pharmacies" and "a partner pharmacy". A dispensing pharmacy is named in the Buchholz class-action complaint, an allegation in a pending case rather than a finding.
  • Published pricing is starting-price only — injectable semaglutide from $199/mo, semaglutide tablets from $249/mo, tirzepatide from $299/mo — and every headline figure carries an asterisk whose conditions do not appear on the page. Standard-dose pricing and any prepaid-bundle price are NOT published: confirmed absent on the rendered pricing pages searched 2026-08-24. Specific standard-dose and bundle figures previously shown here came from a source that could not be retrieved and are withdrawn rather than restated.
  • February 2026 FDA marketing/misbranding warning letter (industry-wide sweep) and a class action over oral tirzepatide; allegations unproven
  • Cancellation and refund difficulty is the dominant complaint theme (BBB B rating, not accredited, 144 complaints)

What is SkinnyRx Weight Loss / GLP-1?

SkinnyRx is operated by Lean Rx, Inc., a Sacramento, California telehealth company available in all 50 states. It says it uses state-licensed pharmacies that compound to individual prescriptions to dispense compounded GLP-1 medications and handles care asynchronously through an app rather than scheduled video visits. Providers are described as US-licensed and board-certified, but none are named on the pages we reviewed, and no compounding pharmacy is named on them either. A dispensing pharmacy is named in the Buchholz class-action complaint — an allegation in a pending case, not a finding, and not a disclosure by SkinnyRx. Compounded medications are not FDA-approved.

Treatment options

Prices as of Sep 24, 2026 — verify current on the brand's site.

Getting started with SkinnyRx

  1. Complete the async online health questionnaire (no scheduled appointment)
  2. A licensed clinician reviews your intake (the specific eligibility and contraindication criteria applied are withdrawn as unverifiable)
  3. If approved, receive a prescription; if not approved, request the full refund within 24-48 hours
  4. Approved compounded medication ships with free overnight delivery
  5. Manage dose adjustments and questions through in-app messaging

Methodology scorecard

Scored on Sep 24, 2026 under methodology v6

5.68/10

Coverage: Checked against 4 recorded withdrawals. Marking matches the wording each withdrawal was recorded in, so the same claim stated differently is not marked.

  • Legitimacy & Accreditation
    Critical

    Evidence (as scored Sep 24, 2026): Real operating US telehealth entity (Lean Rx, Inc.). FDA reviewed skinnyrx.com in December 2025 and found the site represented SkinnyRx as the compounder of its semaglutide and tirzepatide products when it is not, issuing a February 2026 misbranding warning letter. BBB rates it B and it is not accredited. — FDA warning letter — Skinnyrx, Sep 23, 2026

  • Clinical Oversight & Safety
    Critical

    Evidence (as scored Sep 24, 2026): SkinnyRx has sold oral/sublingual tirzepatide. As of 2026-08-10 there is NO trial of an oral or sublingual tirzepatide formulation registered on ClinicalTrials.gov — every registered tirzepatide intervention is subcutaneous. That is an absence in the registry, stated as such; it is not a finding that the route cannot work. Separately, a class action (Buchholz v. Lean Rx, Inc., No. 5:26-cv-00846, N.D. Cal., filed 2026-01-26) ALLEGES the tablets were ineffective and improperly compounded. Those allegations are untested. — clinicaltrials.gov, Aug 10, 2026

  • Sourcing Transparency & Legal Context
    High

    Evidence (as scored Sep 24, 2026): Buchholz v. Lean Rx, Inc., No. 5:26-cv-00846 (N.D. Cal., filed 2026-01-26). Docket record confirmed via the CourtListener API 2026-08-10. — courtlistener.com, Aug 10, 2026

  • Data Privacy & Security
    Medium

    Evidence (as scored Sep 24, 2026): SkinnyRx publishes a Privacy Policy at /privacy (last updated 2026-05-20, ~33,000 characters rendered) with a "Categories of Personal Information We Collect" section, a "Data Security and Data Retention" section, cookie controls, and an explicit carve-out directing protected health information to a separate HIPAA Notice of Privacy Practices. Confirmed on the rendered page 2026-08-24. Two disclosed practices weigh against it, both read from the brand's own pages rather than inferred: the policy states it does NOT honour Do Not Track signals, and the site discloses using hashed and de-identified customer data to build custom audiences for targeted advertising on Facebook, Google and similar platforms - a weight-loss brand doing health-adjacent ad targeting. CONFIRMED ABSENT ON THE RENDERED PAGE: no dedicated consumer-health-data policy of the kind remedymeds publishes. No breach appears on

  • Pricing Transparency & Value
    Critical

    Evidence (as scored Sep 24, 2026):

  • Policy Clarity & Fairness
    High

    Evidence (as scored Sep 24, 2026): SkinnyRx publishes its cancellation and refund policy in full on its own FAQ: a full refund any time before a licensed provider completes the prescription review; non-refundable once the prescription is completed and fulfilment has begun; future months cancellable at any time, before the next shipment is prepared; promotional discounts "reversed or proportionally adjusted" if a committed term is cut short; partially-used subscription periods and bundled subscriptions non-refundable; and no charge at all if the provider finds the patient ineligible, refunded within 24-48 hours. Its /terms publishes binding individual arbitration under AAA rules, a class-action and jury-trial waiver, a 30-day written opt-out from arbitration, a one-year limit to file, California governing law with venue in Sacramento, a small-claims carve-out, and an undertaking to pay AAA fees on claims up to $75,000. Con

  • Popularity & Momentum
    Medium

    Evidence (as scored Sep 24, 2026): Large and growing review base (~5,000 Trustpilot), heavy PR cadence, aggressive affiliate payouts ($500-$600 CPA), New-Year marketing push. — Trustpilot — customer reviews, Jul 24, 2026

  • Quality-under-Growth
    Medium

    Evidence (as scored Sep 24, 2026): Rapid scale accompanied by rising cancellation, billing and dosing complaints on BBB — 144 complaints citing refund issues and undisclosed dosage changes. On the record separately: FDA warning letter #717989 (2026-02-20) for false or misleading marketing. Also on the record: a putative class action, Buchholz v. Lean Rx, Inc., No. 5:26-cv-00846 (N.D. Cal., filed 2026-01-26), whose allegations are untested. — FDA warning letter — Skinnyrx, Aug 11, 2026

  • Access & Speed
    Medium

    Evidence (as scored Sep 24, 2026): SkinnyRx publishes concrete fulfilment timings on its own site: a licensed clinician reviews the intake and, depending on state-specific requirements, issues a prescription or a video visit "within 24 hours"; "you will receive shipping and tracking information within 2 business days"; text and email tracking updates; and "Free overnight shipping on all orders" on the product pages. Confirmed on the rendered page 2026-08-24. CONFIRMED ABSENT ON THE RENDERED PAGE, not merely unretrieved: the site does not publish which states it serves, and publishes no cold-chain or packaging detail. Every timing above is the brand's own attestation with no independent corroboration. THIS SUPERSEDES A RETRIEVAL-GAP FILING whose premise - that no shipping or delivery terms were retrievable - was an artefact of raw-HTML retrieval.

  • Transparency & Disclosure
    Critical

    Evidence (as scored Sep 24, 2026): SkinnyRx names a Medical Director on its product pages (Sajad Zalzala, M.D.) and publishes per-lot quality-control disclosure against named standards: potency within plus or minus 10% of labelled concentration, sterility to USP 797.1 tested every batch, a pH test, and bacterial endotoxin limits to USP 85, which SkinnyRx describes as third-party testing "through FDA- and DEA-compliant labs ... for every compounded lot". Compounded-not-FDA-approved disclaimers appear on every product page and in the site footer, and a Privacy Policy (last updated 2026-05-20) links a HIPAA Notice of Privacy Practices. CONFIRMED ABSENT ON THE RENDERED PAGE, 2026-08-23 - not merely unretrieved: the compounding pharmacies are never named, only referred to as "our partner pharmacies", "503A pharmacies" and "a partner pharmacy"; and no individual prescribing clinician is named, only "All our providers are based — FDA warning letter — Skinnyrx, Sep 23, 2026

  • Support & Care Model
    Supporting

    Evidence (as scored Sep 24, 2026): SkinnyRx publishes its support model on its own site: "unlimited access to our patient care team and providers", clinician consultation about progress, side effects or dosage "at no extra cost through our patient portal", 24/7 access to medical providers, and a provider-guides page offering "unlimited appointments, messaging, and support". Contact channels are published — [email protected] and 1-888-979-9580. Confirmed on the rendered pages 2026-08-24 (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted): homepage, /products/semaglutide-injectable and /products/tirzepatide-injectable. Weighed against that, the checkable service record is poor: the BBB profile carries 144 complaints with refund and cancellation handling as the dominant theme, and the brand is rated B and not accredited. THIS SUPERSEDES A RETRIEVAL-GAP FI

  • Titration Autonomy
    High

    Evidence (as scored Sep 24, 2026):

  • Weight-Management Care Model
    Medium

    Evidence (as scored Sep 24, 2026): ClinicalTrials.gov returned 20 tirzepatide studies matching oral/sublingual terms on 2026-08-10, none registering an oral or sublingual tirzepatide formulation; every tirzepatide arm is subcutaneous. — clinicaltrials.gov, Aug 10, 2026

  • Eligibility Screening
    High

    Evidence (as scored Sep 24, 2026): SkinnyRx publishes its screening process on its own site: a pre-qualification medical intake, then "a licensed clinician will review your information". — dailymed.nlm.nih.gov, Sep 24, 2026

Pricing & cancellation

Visit SkinnyRx

All-in price

Cost structure
No long-term contract for month-to-month, but prepaid 12-month bundles are non-refundable
Insurance vs. cash
Cash-pay
Deal structure
Cancellation
Month-to-month; cancellation reported as difficult, dominant complaint theme
Forced subscription
Not required

Pros & cons

Pros

  • Strong Trustpilot rating (~4.7, ~5,000 reviews)
  • No scheduled appointment required; nationwide availability; async in-app care
  • Multiple drug formats (injection, sublingual, tablet) and month-to-month option

Cons

  • Feb 2026 FDA warning letter for misleading marketing + class action over oral tirzepatide

Safety

Talk to a licensed clinician

Common GLP-1 side effects include nausea, vomiting, diarrhea, constipation, and injection-site reactions. SkinnyRx screens through an async questionnaire rather than a live visit. A class action alleges some products were distributed without a genuine medical evaluation; those allegations are unproven. Because these medications are compounded, they are not individually FDA-approved, and a licensed clinician should determine whether treatment is appropriate. This is information for comparing providers, not medical advice.

Common side effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Injection-site reactions

Who should not take it

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple endocrine neoplasia syndrome type 2 (MEN2)
  • Pregnancy
  • Breastfeeding
  • History of pancreatitis

The bottom line

SkinnyRx delivers quick, nationwide access to compounded GLP-1 medications in several formats at marketing-friendly headline prices, backed by a high-volume Trustpilot score. Weigh that against a compounding pharmacy it does not name on the pages we reviewed, an intro-price-then-standard-price pattern, a February 2026 FDA marketing warning letter, a class action over its oral tirzepatide, and a recurring pattern of cancellation and refund complaints before enrolling.

Visit SkinnyRx

We may earn a commission if you sign up through this link. It never affects rankings or scores. Not medical advice.

See how SkinnyRx ranks among GLP-1 providers

What changed & why

This brand's own history — every re-review and methodology recompute, logged. Rankings change when the evidence or the rules change, never for payment. See the site-wide methodology ledger for version history.

  1. Sep 14, 2026Methodologymethodology v65.655.68

    We changed how this score is calculated, and Weight Management / GLP-1 score moved from 5.65 to 5.68. 9 of the factors behind it moved. How we score.

    Assessed coverage rose 7 → 14 — this score rests on more evidence than the previous one.

  2. Aug 23, 2026Methodologymethodology v35.595.65

    We changed how this score is calculated, and Weight Management / GLP-1 score moved from 5.59 to 5.65. 8 of the factors behind it moved. How we score.

    8 factors withdrawn — assessed coverage fell 15 → 7. Part of any score movement here reflects evidence we retracted, not a change in the brand.

  3. Jul 24, 2026Re-review8.005.59

    Weight Management / GLP-1 score moved from 8.00 to 5.59 after a fresh review of the evidence. 15 of the factors behind it moved.

    Whether this score rests on more or less evidence than the previous one is not recorded — the earlier score did not store how many factors it assessed.

Frequently asked questions

Is SkinnyRx legit?

SkinnyRx is a real US telehealth service operated by Lean Rx, Inc. and says it dispenses through state-licensed pharmacies that compound to individual prescriptions. That said, its LegitScript accreditation could not be verified, the FDA issued a February 2026 marketing/misbranding warning letter to Lean Rx (part of an industry-wide sweep), and the company faces a class action over its oral tirzepatide. Its compounding pharmacy is not named on the site.

How much does SkinnyRx really cost?

SkinnyRx publishes starting prices on its own site: compounded injectable semaglutide from $199/mo, semaglutide tablets from $249/mo, and tirzepatide from $299/mo. Every headline figure is an "as low as" or "from" price carrying an asterisk whose conditions do not appear on the page, and microdosing is offered without a stated price — so the advertised rate is a floor, not a typical cost. What the standard non-intro monthly cost is, and whether a prepaid bundle exists at all, are not published: confirmed absent on the rendered pricing pages searched 2026-08-24. FindDrugs previously carried specific standard-dose and bundle figures here; their only source could not be retrieved, so they are withdrawn rather than restated — we do not publish a price we could not verify. On the record from the brand's own pages: FSA/HSA cards accepted, free overnight shipping on all orders, no contracts with cancellation at any time, and Affirm financing disclosed at rates from 0-36% APR.

Can I cancel SkinnyRx easily?

Cancellation is the most common complaint. Billing is month-to-month by default with a full refund within 24-48 hours if you are not approved, but orders become non-refundable once fulfillment begins and prepaid bundles are non-refundable. Confirm the terms before you buy and monitor your payment method.

Are the sublingual and oral GLP-1 versions effective?

The efficacy of sublingual and oral routes for these peptides is contested, and SkinnyRx's oral tirzepatide is the subject of a class action alleging there is no clinical evidence it produces a therapeutic effect delivered orally or sublingually. Those allegations are unproven. Discuss the route and evidence with a licensed clinician.

Work at SkinnyRx?

If something here is wrong or out of date, send us a correction request. We read every one and decide what changes — it does not edit the review or move a score.

Sources & how we researched this

Scored on 14 of 14 factors · 8 sources cited

Brand site

Regulatory

Reviews

Other

What we couldn't verify

  • Homepage, pricing and eligibility pages at skinnyrx.com are JavaScript-rendered, so a RAW HTML fetch of them yielded only 8 characters (2026-08-10). RESOLVED 2026-08-24: the automated rendered retrieval path reads them normally; the homepage alone returns ~17,900 characters including four published starting prices. This was a limitation of our retrieval, never a property of the brand, and the claims built on it have been corrected.
  • No detailed SkinnyRx privacy/security policy retrievable - data-privacy scored on standard-telehealth assumption.
  • LegitScript accreditation status inconsistent across sources; not confirmed on LegitScript directly.
  • The dispensing pharmacy is not named by SkinnyRx on the pages we reviewed. A pharmacy is named in the pending class-action complaint — an allegation rather than a finding — so we do not restate the name here.
  • Withdrawn — SkinnyRx pricing of $261.75/month for standard-dose compounded semaglutide. SkinnyRx pricing of $261.75/month for standard-dose compounded semaglutide remains WITHDRAWN: its only source returned HTTP 403 (retrieval-failed, not disproved) and no originating source states that figure. CORRECTED 2026-08-24 — the reason previously attached to this withdrawal, which asserted that the brand served no readable content and published no retrievable price at all, was FALSE and an artefact of raw-HTML retrieval. The brand publishes starting prices on its own homepage (compounded semaglutide from $199, semaglutide tablets from $249, tirzepatide from $299). The $261.75 figure is simply not among them, which is why the withdrawal itself stands. Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • Withdrawn — SkinnyRx does not publish its compounding pharmacy names. The claim that SkinnyRx does not publish its compounding pharmacy names is WITHDRAWN as sourced — the 403'd page cannot support it. The absence is instead recorded against the record we do have: no pharmacy is named in the FDA warning letter correspondence or on any retrievable brand page.
  • SkinnyRx support-model detail was WITHDRAWN on 2026-08-10 because its source 403'd and, it was said, nothing was retrievable on the brand's own site. RESOLVED 2026-08-24: the second half of that reason was false — a rendered read returns the brand's published support model in full (unlimited patient-care-team access, no-extra-cost clinician consults through the portal, 24/7 provider access, published phone and email). The factor is now scored on that rendered evidence rather than excluded. The service-quality signal from the BBB complaint record is carried in the observation itself and on the ReviewSource axis, where it belongs.
  • This entry withdrew TWO different claims on one reason, and the rendered read settles them in OPPOSITE directions — so they are now recorded separately. (a) THE REFUND TERMS ARE REINSTATED: "non-refundable once fulfilment has begun" and "bundled subscriptions are non-refundable" are stated verbatim on the brand's own FAQ, so the withdrawal reason — syndicated-newswire sourcing with nothing retrievable from the brand — no longer holds for them. (b) BMI ELIGIBILITY OF 27+ REMAINS WITHDRAWN, and on stronger grounds than before: no BMI threshold of any kind is published anywhere on the rendered site — confirmed absent on the rendered pages searched, not merely unretrieved. A withdrawal is not reversed because its stated reason was wrong; each specific is re-checked on its own. Confirmed on the rendered pages 2026-08-24 (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted): homepage, /products/semaglutide-injectable and /products/tirzepatide-injectable.
  • Withdrawn — SkinnyRx data-privacy assessment. SkinnyRx data-privacy assessment is WITHDRAWN. The cited quote conceded its own emptiness — "standard US telehealth data-handling context implied but specific privacy terms not surfaced" — which is an inference, not evidence, and it was carrying a scored factor.
  • SkinnyRx "free overnight shipping" was WITHDRAWN on 2026-08-10 because its source was a syndicated newswire placement and our raw fetch of the brand's site could not read it. REINSTATED 2026-08-24: the brand states "Free overnight shipping on all orders" on its own rendered product pages. The withdrawal rested entirely on a retrieval failure rather than on an absence, and the retrieval failure is resolved. Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • Withdrawn — SkinnyRx eligibility criteria (BMI 27+, clinician-determined contraindications). SkinnyRx eligibility criteria (BMI 27+, clinician-determined contraindications) are WITHDRAWN — syndicated newswire sourcing, unconfirmable against the brand.
  • Withdrawn — SkinnyRx titration characterisation ("some users disappointed when prescribed lower starting doses"). The SkinnyRx titration characterisation ("some users disappointed when prescribed lower starting doses") is WITHDRAWN — anonymous user sentiment on a review site, with no verifiable base and no originating record.
  • pricing-transparency-value: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 338). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • transparency-disclosure: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 339). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • support-care-model: this factor was re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) on 2026-08-13, on the premise that the brand's own pages could not be read at all. ⚠️ THAT PREMISE IS FALSE — a rendered read returns the full site. UNLIKE THE OTHER SEVEN, THIS EXCLUSION HAS NOT YET BEEN REVISITED ON RENDERED EVIDENCE and remains open: the factor is still excluded and still re-normalized out of the score, on a reason that no longer holds. It is recorded here rather than left reading as though it were justified. Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • policy-clarity-fairness: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 340). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • data-privacy-security: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 344). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • access-speed: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 343). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • glp1-eligibility-screening: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 341). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • glp1-titration-autonomy: this factor was re-encoded as a RETRIEVAL GAP on 2026-08-13, on the premise that the brand's own pages could not be read at all and therefore nothing could be established about what it discloses. THAT PREMISE WAS FALSE — our raw fetcher could not execute the site's JavaScript, which is a limitation of ours and not a property of the brand. SUPERSEDED 2026-08-24: the factor is now scored on rendered evidence read from the brand's own pages (observation 342). Corrected 2026-08-24 against a rendered read of the brand's own site (automated rendering path, terms-gated; skinnyrx.com is the one host the rendered-retrieval spike settled as permitted).
  • The Trustpilot rating shown on this page is NOT withdrawn, but it cannot be re-verified and it disagrees with itself: the verdict and key takeaways state 4.8 across 5,266 reviews while the pros list states ~4.7 across ~5,000. trustpilot.com is refused on terms — its Terms of Use ban access "through use of automated technologies such as AI agents or screen scrapers" — so we have no route to the figure that we are permitted to use, and cannot settle which of the two is right. Both are published as retrieved on 2026-07-24 and treated as unverifiable from that date forward. This is the fourth brand in the corpus carrying a Trustpilot figure from a host we may not retrieve; the consumer-sentiment observation resting on it is recorded as undermined and has NOT been changed here. (2026-08-25)
Last reviewed Sep 24, 2026 · methodology v6View the ledger

Top pick

SkinnyRx 5.68/10